Ionis Pharmaceuticals (MEX:IONS) Total Stockholders Equity: MXN7,673 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
71 GF Score
Price MXN1,150.00
GF Value MXN1,061.81
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Total Stockholders Equity?

Ionis Pharmaceuticals MEX:IONS 71 Total Stockholders Equity is MXN7,673 Mil as of Jun. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 71/100 and a GF Value™ of MXN1,061.81. The stock has 5 warning signs investors should review.

Ionis Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was MXN7,673 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ionis Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 was MXN46.32. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ionis Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 was 5.38.

Ionis Pharmaceuticals  (MEX:IONS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ionis Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(7672.971-0)/165.637
=46.32

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ionis Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(13139.097 + 28154.345) / 7672.971
=5.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Total Stockholders Equity Related Terms

Ionis Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Total Stockholders Equity Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,831.41 11,169.01 6,563.70 12,270.47 8,806.39

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,894.86 11,336.11 8,806.39 8,861.52 7,672.97
MEX:IONS
71GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN7,673 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Total Stockholders Equity of MXN7,673 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Total Stockholders Equity too high?
Ionis Pharmaceuticals' current Total Stockholders Equity is MXN7,673 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Total Stockholders Equity compare to KYMR and PRAX?
Ionis Pharmaceuticals' Total Stockholders Equity of MXN7,673 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Total Stockholders Equity is MXN7,673 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Total Stockholders Equity of MXN7,673 Mil. The stock's GF Value™ is MXN1,061.81, compared to a current price of MXN1,150.00 — trading 8.3% above its estimated fair value. The current Total Stockholders Equity is MXN7,673 Mil. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Total Stockholders Equity is MXN7,673 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 8.3% above its estimated GF Value™ of MXN1,061.81.

Key valuation signals for MEX:IONS:

  • Total Stockholders Equity: MXN7,673 Mil
  • GF Value™: MXN1,061.81 vs. price of MXN1,150.00 (8.3% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for MEX:IONS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN1,061.81
GF Value